News

After about two years of treatment with the experimental therapies tobevibart and elebsiran, nearly nine out of 10 evaluable…

Researchers have identified three proteins that may be key targets for treating primary sclerosing cholangitis (PSC), and one of these proteins may also be…

A global clinical trial testing Mirum Pharmaceuticals‘ maralixibat for treatment-resistant itching, or pruritus, associated with rare cholestatic conditions is expected to complete patient…

AX-0810, an experimental treatment for biliary atresia and primary sclerosing cholangitis (PSC), has so far been well tolerated in early clinical testing. Initial…

Bepirovirsen added to standard-of-care medications led to higher functional cure rates for people with chronic hepatitis B than standard treatments alone, according to top-line…

Vitamin D was shown to ease the effects of liver inflammation and damage in primary biliary cholangitis (PBC), a chronic form of cholangitis,…

Low vitamin D levels in the first trimester of pregnancy are significantly associated with an increased risk of developing intrahepatic cholestasis of pregnancy (ICP),…

Madrigal Pharmaceuticals, the maker of Rezdiffra (resmetiron), has acquired three new experimental treatments for metabolic dysfunction-associated steatohepatitis (MASH), a severe form of fatty…

Two adult brothers with impaired vision due to glaucoma, a serious eye condition that may lead to irreversible vision loss, were found to have…

Health Canada has expanded its approval of Abbvie’s oral therapy Maviret (glecaprevir/pibrentasvir), making it the first eight-week, pan-genotypic treatment available for both acute and…